Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Biotech
Sanofi drops dwarfism drug as part of rare disease clear-out
Sanofi has halted work on a phase 2 candidate for a rare growth disorder drug as well as two other rare disease assets and one of its mRNA flu shots.
James Waldron
Jul 25, 2024 7:58am
Sponsored
Cell and gene therapies: Navigating the cold chain revolution
Jul 22, 2024 8:00am
Pfizer gene therapy reduces bleeds in ph. 3 hemophilia A trial
Jul 24, 2024 8:44am
Artiva upsizes IPO to $167 million
Jul 19, 2024 4:56am
Caribou cuts NK program, lays off 12% to fund CAR-T trials
Jul 17, 2024 5:41am
Lexeo links gene therapy to improvements in rare heart disease
Jul 15, 2024 9:46am
More News
Artiva sets out $135M IPO to push NK cell therapy through trials
Jul 15, 2024 8:33am
CRISPR gene therapy for deafness works in young adult mice
Jul 11, 2024 9:15am
uniQure's interim data shows gene therapy slows Huntington’s
Jul 9, 2024 9:25am
Beacon attracts $170M series B to fund eye disease gene therapy
Jul 3, 2024 5:00am
See more stories